Brad L. Hart


Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.


Brad Hart works with private and public companies in the financial services, healthcare and technology industries on a broad range of transactional, corporate governance and securities law matters, including mergers and acquisitions, securities offerings and day-to-day SEC reporting and disclosure compliance.

Brad focuses his practice on:

  • Mergers & Acquisitions – Representing public and private companies and private equity clients on a wide variety of transactions.
  • Securities Offerings – Assisting clients in connection with public offerings of debt and equity securities, Rule 144A offerings and private placements.
  • Corporate Governance – Advising public company clients on securities law reporting and disclosure, including the preparation of Form 10-Ks, 10-Qs, 8-Ks, proxy statements and earnings releases, regulatory and stock exchange compliance and best practices, and shareholder activism matters.
  • Venture Investments – Assisting venture capital funds and other companies in securing and successfully completing early and growth stage investments.

Brad has advised on many multi-billion dollar merger & acquisition transactions and public and private securities offerings worth over $3.5 billion, and has been an integral part of multiple transactions that were recognized by M&A Advisor as “Deals of the Year” in various categories.


American Health Law Association (AHLA)